New University-Based Research Study Demonstrates A Novel Mechanism Of Action For New Hair Formulation

Rensselaer, New York (PressExposure) August 24, 2009 -- In the current issue of the peer-reviewed medical journal Evidence Based Complimentary & Alternative Medicine (eCAM) scientists at The University of Albany, Center For Functional Genomics, working collaboratively with Advanced Restoration Technologies (ART), report the positive findings of a series of basic science experiments recently undertaken to test a novel, naturally derived hair loss treatment formula, TS050508A.

Because chronic inflammation of the hair follicle is considered a contributing factor in the onset and progression of androgenetic alopecia (AGA), study investigators Sridar Chittur, Brian Parr & Geno Marcovici sought to measure the test material’s activity in blocking key markers of pathologic inflammation by using a well-validated molecular assay representative of hair follicle keratinocytes. Specifically, the research team found that the test compound suppressed gene expression of several inflammatory chemokines potentially linked to hair loss.

In addition to anti-inflammatory agents, TS050508A was formulated with a subset of botanically derived, highly potent 5 alpha-reductase (5AR) inhibitors. 5AR catalyzes the conversion of testosterone (T) to its more pathological metabolite dihydrotestosterone (DHT). DHT is a well-known trigger of pattern hair loss. Thus, by combining targeted anti-inflammatory agents with potent 5AR inhibitors the test composition was designed to offer enhanced clinical efficacy over conventional monotherapy.

Lead scientist for the study Sridar Chittur, Ph.D. has been at the forefront of molecular research authoring published works ranging from degenerative mitral valve disease (DMVD), to transcriptional changes associated with oxidative stress in the mitochondria. Co-author Brian Parr, Ph.D. brings a wealth of basic science expertise to the project with a number of peer-reviewed papers describing novel gene transcription and protein expression profiles in the Wnt and Frizzled pathways.

Study co-author Geno Marcovici, Ph.D. has been active in the hair loss field for more than a decade. His research efforts include the first published clinical trial successfully testing naturally derived 5 alpha reductase inhibitors in the setting of pattern hair loss. Explaining the importance of validating ART’s proprietary formulations Marcovici notes that “[a]side from HairGenesis®, the naturally-derived hair treatments commercially available offer little or no objective evidence that they work. On the other hand, the drug-based treatments that do work come with potentially serious negative side effects. This tends to render HairGenesis® as a unique proposition in the category. ”

Link To Published Study

About HairGenesis(R)

Combining scientific validation with the safety of natural ingredients, ART’s product line HairGenesis® represents a unique therapeutic platform in the hair loss treatment category. Prior to focusing on basic science research, ART established a 10-year track record as a surgical center for IRB-monitored clinical investigation, testing new drugs as well as medical devices. ART-based published studies include those undertaken on behalf of Organogenesis, Canton, MA and Procyte Corporation, Kirkland, WA. It was from this research platform that Hair Genesis™ was originally conceived and created.

Hair Genesis® is noteworthy as the first, and so far only, naturally derived hair loss treatment supported by published 3rd Party clinical and basic science research. Hair Genesis® is sold in health clinics as well as internet-based distribution. Online distributors of Hair Genesis® include,,, &

For more information contact: ?Geno Marcovici, Ph.D.
Advanced Restoration Technologies Inc., DBA Hair Genesis®

Press Release Source:

Press Release Submitted On: September 04, 2009 at 6:33 pm
This article has been viewed 54533 time(s).